Here’s how SpaceX’s debut stacks up against other major IPOs

SpaceX’s IPO is off to a strong start, with the stock rising to $186 from a $150 debut price and lifting the company’s market value above $2.4 trillion after raising $85.7 billion. The article highlights record-breaking demand, but also notes profitability remains unclear: SpaceX reported $18.7 billion in 2025 revenue versus $4.9 billion in net losses. Analysts at Morningstar estimate fair value at $780 billion, implying substantial downside versus the current valuation.

Analysis

The immediate winner is not just the issuer; it is every platform that monetizes attention around primary issuance. A mega-print of this size expands the fee pool, but the bigger second-order effect is the normalization of extreme first-day pops, which encourages issuers to optimize for headline valuation and aftermarket scarcity rather than clean price discovery. That tends to help bookrunners, data/market-structure vendors, and media franchises in the short run, while quietly increasing execution risk for future offerings if buyers start demanding larger discounts or stronger lockups.

The most interesting read-through is to sentiment-sensitive IPO comps rather than the obvious “space” bucket. FIG and ABNB benefit from a renewed willingness to underwrite growth at almost any price, but that also means their multiples become more vulnerable if the market starts re-pricing the risk of paying up for unprofitable or long-dated monetization stories. NDAQ is the structural loser if a wave of blockbuster private-market monetizations diverts activity away from more traditional listed issuance and secondary trading; over months, the bigger risk is not one deal, but a pipeline shift that compresses quality-adjusted listing economics.

The contrarian point is that a giant first-day move can be a sign of scarcity, not durability. For SpaceX-like assets, the key variable is not launch volume or brand, but whether incremental capital spending can sustain growth without margin erosion; if investor enthusiasm broadens before profitability proves out, the stock becomes a crowded-duration trade vulnerable to any margin miss, launch setback, or competitive progress from lower-cost entrants. Morningstar-style valuation skepticism is probably too early for a near-term fade, but too low for a multi-quarter model if competition closes the technology gap faster than expected.

Key Decisions for Investors

• Long FIG vs short NDAQ for 4-8 weeks: express the view that hype-driven issuance benefits high-beta growth re-ratings more than exchange economics; target 1.5-2.0x upside on FIG relative to NDAQ if IPO enthusiasm remains elevated.
• Buy near-dated put spreads on any fresh mega-IPO after the first 3-5 trading sessions: the asymmetric risk is mean reversion once initial scarcity demand clears; structure for limited premium outlay and 2-4x payoff if the stock fades 10-15%.
• Add ABNB on weakness, not strength, over the next 1-2 months: a rising-risk-appetite tape can lift all long-duration assets, but ABNB benefits less directly than pure IPO sentiment names; use it as a lower-beta beneficiary with a tighter stop than FIG.
• Initiate a small tactical short in NDAQ into continued IPO frenzy, with a 6-12 month horizon: upside from deal volume is real, but the market may be overestimating how much incremental issuance accrues to exchange economics versus bankers and private-market venues.
• Keep a standing watchlist for post-IPO lockup expiries in hot growth names: if the market keeps rewarding first-day pops, the best risk/reward will often be shorting into the first meaningful supply overhang rather than fading the debut.